JP2011526293A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011526293A5 JP2011526293A5 JP2011516635A JP2011516635A JP2011526293A5 JP 2011526293 A5 JP2011526293 A5 JP 2011526293A5 JP 2011516635 A JP2011516635 A JP 2011516635A JP 2011516635 A JP2011516635 A JP 2011516635A JP 2011526293 A5 JP2011526293 A5 JP 2011526293A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- effective amount
- pharmaceutical composition
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000003937 drug carrier Substances 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 206010065040 AIDS dementia complex Diseases 0.000 claims 3
- 206010001889 Alveolitis Diseases 0.000 claims 3
- 206010002329 Aneurysm Diseases 0.000 claims 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims 3
- 208000031886 HIV Infections Diseases 0.000 claims 3
- 208000037357 HIV infectious disease Diseases 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 206010037660 Pyrexia Diseases 0.000 claims 3
- 208000006045 Spondylarthropathies Diseases 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 3
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 3
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 230000003589 nefrotoxic effect Effects 0.000 claims 3
- 201000008383 nephritis Diseases 0.000 claims 3
- 231100000381 nephrotoxic Toxicity 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 201000005671 spondyloarthropathy Diseases 0.000 claims 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 3
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 claims 2
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 claims 2
- 102000009410 Chemokine receptor Human genes 0.000 claims 2
- 108050000299 Chemokine receptor Proteins 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 102000010907 Cyclooxygenase 2 Human genes 0.000 claims 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 102000004500 CCR1 Receptors Human genes 0.000 claims 1
- 108010017319 CCR1 Receptors Proteins 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 230000000954 anitussive effect Effects 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 230000001088 anti-asthma Effects 0.000 claims 1
- 229940127003 anti-diabetic drug Drugs 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 239000000924 antiasthmatic agent Substances 0.000 claims 1
- 239000003529 anticholesteremic agent Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940124623 antihistamine drug Drugs 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003434 antitussive agent Substances 0.000 claims 1
- 229940124584 antitussives Drugs 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000000850 decongestant Substances 0.000 claims 1
- 229940124581 decongestants Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000938 histamine H1 antagonist Substances 0.000 claims 1
- 230000004957 immunoregulator effect Effects 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims 1
- 229960004963 mesalazine Drugs 0.000 claims 1
- 229940124641 pain reliever Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 230000001624 sedative effect Effects 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7539408P | 2008-06-25 | 2008-06-25 | |
| US61/075,394 | 2008-06-25 | ||
| US12/490,477 US8299098B2 (en) | 2008-06-25 | 2009-06-24 | Piperidinyl derivative as a modulator of chemokine receptor activity |
| US12/490,477 | 2009-06-24 | ||
| PCT/US2009/048564 WO2009158452A1 (en) | 2008-06-25 | 2009-06-25 | Piperidinyl derivative as a modulator of chemokine receptor activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011526293A JP2011526293A (ja) | 2011-10-06 |
| JP2011526293A5 true JP2011526293A5 (enExample) | 2012-03-08 |
| JP5357965B2 JP5357965B2 (ja) | 2013-12-04 |
Family
ID=41060069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011516635A Expired - Fee Related JP5357965B2 (ja) | 2008-06-25 | 2009-06-25 | ケモカイン受容体活性のモジュレーターとしてのピペリジン誘導体 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8299098B2 (enExample) |
| EP (1) | EP2323983B1 (enExample) |
| JP (1) | JP5357965B2 (enExample) |
| KR (1) | KR20110023865A (enExample) |
| CN (1) | CN102076663B (enExample) |
| AU (1) | AU2009262219B2 (enExample) |
| BR (1) | BRPI0914539A2 (enExample) |
| CA (1) | CA2729016A1 (enExample) |
| CL (1) | CL2010001566A1 (enExample) |
| CO (1) | CO6321247A2 (enExample) |
| CY (1) | CY1114994T1 (enExample) |
| DK (1) | DK2323983T3 (enExample) |
| EA (1) | EA021224B1 (enExample) |
| ES (1) | ES2447740T3 (enExample) |
| HR (1) | HRP20140071T1 (enExample) |
| IL (1) | IL209832A (enExample) |
| MX (1) | MX2010013664A (enExample) |
| NZ (1) | NZ589909A (enExample) |
| PE (1) | PE20110103A1 (enExample) |
| PL (1) | PL2323983T3 (enExample) |
| PT (1) | PT2323983E (enExample) |
| SI (1) | SI2323983T1 (enExample) |
| TW (1) | TWI433838B (enExample) |
| WO (1) | WO2009158452A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI433838B (zh) * | 2008-06-25 | 2014-04-11 | 必治妥美雅史谷比公司 | 作為趨化因子受體活性調節劑之六氫吡啶衍生物 |
| WO2011044197A1 (en) * | 2009-10-07 | 2011-04-14 | Bristol-Myers Squibb Company | Spirocyclic compounds as modulators of chemokine receptor activity |
| US8410139B2 (en) * | 2009-10-07 | 2013-04-02 | Bristol-Myers Squibb Company | Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity |
| US8642622B2 (en) * | 2010-06-16 | 2014-02-04 | Bristol-Myers Squibb Company | Piperidinyl compound as a modulator of chemokine receptor activity |
| AR087277A1 (es) | 2011-07-21 | 2014-03-12 | Bristol Myers Squibb Co | Composiciones biodisponibles de compuestos amorfos de piperidinilo, composicion farmaceutica, metodos |
| WO2013162984A1 (en) | 2012-04-25 | 2013-10-31 | Bristol-Myers Squibb Company | Methods for identifying subjects with an increased likelihood of responding to ccr1 antagonist |
| US9257178B1 (en) * | 2014-11-26 | 2016-02-09 | Taiwan Semiconductor Manufacturing Company Limited | Devices and methods for writing to a memory cell of a memory |
| US10079235B2 (en) * | 2016-08-31 | 2018-09-18 | Micron Technology, Inc. | Memory cells and memory arrays |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60163855A (ja) | 1984-02-06 | 1985-08-26 | Mitsubishi Chem Ind Ltd | アルギニン誘導体および薬剤として許容され得るその酸付加塩 |
| GB9104656D0 (en) | 1991-03-05 | 1991-04-17 | Zambeletti Spa L | Pharmaceuticals |
| DE4243858A1 (de) | 1992-12-23 | 1994-06-30 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US5459151A (en) | 1993-04-30 | 1995-10-17 | American Home Products Corporation | N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents |
| US5492920A (en) | 1993-12-10 | 1996-02-20 | Merck & Co., Inc. | Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone |
| WO1995034311A1 (en) | 1994-06-13 | 1995-12-21 | Merck & Co., Inc. | Piperazine compounds promote release of growth hormone |
| CA2226740A1 (en) | 1995-07-13 | 1997-01-30 | Mitsuyoshi Azuma | Piperazine derivative and its uses |
| EP0944388A4 (en) | 1996-04-03 | 2001-08-16 | Merck & Co Inc | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE |
| ATE266673T1 (de) | 1996-09-10 | 2004-05-15 | Boehringer Ingelheim Pharma | Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| WO1998017625A1 (en) | 1996-10-22 | 1998-04-30 | Daiichi Pharmaceutical Co., Ltd. | Novel remedies for infectious diseases |
| US5847148A (en) | 1997-04-10 | 1998-12-08 | Pharmacia & Upjohn Company | Thiadiazole derivatives useful for the treatment of diseases related to connective tissue degradation |
| JPH1171350A (ja) * | 1997-06-17 | 1999-03-16 | Takeda Chem Ind Ltd | ヒドロキシピペリジン化合物およびその剤 |
| ZA987385B (en) | 1997-08-19 | 2000-04-18 | Lilly Co Eli | Growth hormone secretagogues. |
| ZA987383B (en) | 1997-08-19 | 2000-02-17 | Lilly Co Eli | Treatment of congestive heart failure with growth hormone secretagogues. |
| AU3748399A (en) | 1998-04-16 | 1999-11-01 | Texas Biotechnology Corporation | N,n-disubstituted amides that inhibit the binding of integrins to their receptors |
| PT1140830E (pt) | 1998-12-17 | 2005-08-31 | Wyeth Corp | Derivados de arilpiperidina e aril-1,2,5,6-tetra-hidro-piridina amida possuindo actividade receptora de 5ht1a |
| WO2000051609A1 (en) | 1999-03-02 | 2000-09-08 | Merck & Co., Inc. | 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity |
| US6391865B1 (en) | 1999-05-04 | 2002-05-21 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| JP2003505435A (ja) | 1999-06-04 | 2003-02-12 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン−４受容体ゴニストとしての置換ピペリジン |
| DE10041402A1 (de) | 2000-08-23 | 2002-03-14 | Morphochem Ag | Neue Verbindungen, die Faktor Xa-Aktivität inhibieren |
| JP2001354657A (ja) | 2000-06-09 | 2001-12-25 | Sds Biotech:Kk | 置換ピペラジン誘導体及び農園芸用殺菌剤 |
| AU2001268607A1 (en) | 2000-06-21 | 2002-01-02 | Bristol-Myers Squibb Company | Piperidine amides as modulators of chemokine receptor activity |
| DE10049699A1 (de) * | 2000-10-07 | 2002-05-08 | Bosch Gmbh Robert | Anker für eine elektrische Maschine sowie Verfahren zu dessen Herstellung |
| EP1368340B1 (en) | 2001-01-23 | 2005-08-10 | Eli Lilly And Company | Piperazine derivatives as melanocortin receptor agonists |
| HUP0401544A2 (hu) | 2001-03-02 | 2004-12-28 | Bristol-Myers Squibb Company | Melanokortin receptor modulátoraiként hasznos vegyületek és a vegyületeket tartalmazó gyógyszerkészítmények |
| US6887924B2 (en) | 2001-05-11 | 2005-05-03 | Multisorb Technologies, Inc. | Pressed adsorbent and method of fabrication thereof |
| DE10124041A1 (de) | 2001-05-16 | 2002-11-21 | Graffinity Pharm Design Gmbh | Protease Inhibitoren |
| ATE411021T1 (de) | 2001-07-18 | 2008-10-15 | Merck & Co Inc | Überbrückte piperidinderivate als melanocortin- rezeptor-agonisten |
| US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
| KR100991616B1 (ko) | 2001-09-06 | 2010-11-04 | 쉐링 코포레이션 | 안드로겐 의존성 질환 치료용 17β-하이드록시스테로이드데하이드로게나제 유형 3 억제제 |
| US20030229067A1 (en) | 2001-12-20 | 2003-12-11 | Arlindo Castelhano | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use |
| EA007468B1 (ru) | 2001-12-20 | 2006-10-27 | Оси Фармасьютикалз, Инк. | Пиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение |
| US7041681B2 (en) | 2002-04-29 | 2006-05-09 | Janssen Pharmaceutica N.V. | Compounds as opioid receptor modulators |
| US20050256130A1 (en) | 2002-06-12 | 2005-11-17 | Chemocentryx, Inc. | Substituted piperazines |
| AU2003236500B9 (en) | 2002-06-12 | 2009-07-02 | Chemocentryx, Inc. | 1-aryl-4-substituted piperazine derivatives for use as CCR1 antagonists for the treatment of inflammation and immune disorders |
| SE0202838D0 (sv) * | 2002-09-24 | 2002-09-24 | Astrazeneca Ab | Chemical compounds |
| GB0224917D0 (en) | 2002-10-25 | 2002-12-04 | Novartis Ag | Organic compounds |
| CA2503844A1 (en) | 2002-10-30 | 2004-05-21 | Merck & Co., Inc. | Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity |
| TWI291467B (en) | 2002-11-13 | 2007-12-21 | Millennium Pharm Inc | CCR1 antagonists and methods of use therefor |
| CA2512886A1 (en) | 2003-02-28 | 2004-09-10 | Galderma Research & Development, S.N.C. | Ligands that modulate lxr-type receptors |
| US6846836B2 (en) | 2003-04-18 | 2005-01-25 | Bristol-Myers Squibb Company | N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase |
| EP1633737A1 (en) | 2003-06-13 | 2006-03-15 | Schering Aktiengesellschaft | Quinolyl amide derivatives as ccr-5 antagonists |
| GB0315203D0 (en) | 2003-06-28 | 2003-08-06 | Celltech R&D Ltd | Chemical compounds |
| FR2862967B1 (fr) | 2003-12-01 | 2006-08-04 | Sanofi Synthelabo | Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique |
| DE10358539A1 (de) | 2003-12-15 | 2005-07-07 | Merck Patent Gmbh | Carbonsäureamidderivate |
| SE0400208D0 (sv) * | 2004-02-02 | 2004-02-02 | Astrazeneca Ab | Chemical compounds |
| WO2005084672A1 (de) | 2004-03-03 | 2005-09-15 | Boehringer Ingelheim International Gmbh | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
| GB0412468D0 (en) | 2004-06-04 | 2004-07-07 | Astrazeneca Ab | Chemical compounds |
| WO2006004741A2 (en) | 2004-06-28 | 2006-01-12 | Incyte Corporation | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors |
| GEP20094843B (en) | 2004-06-28 | 2009-11-25 | Incyte Corp | 3-aminocyclopentane carboxamides as modulators of chemokine receptors |
| US7723360B2 (en) | 2004-08-06 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Alkyl-and piperidine-substituted benzimidazole derivatives |
| JP4688889B2 (ja) * | 2005-02-16 | 2011-05-25 | シェーリング コーポレイション | Ｃｘｃｒ３アンタゴニスト活性を有する、アミン結合ピリジルおよびフェニルで置換されたピペラジン−ピペリジン |
| US7601844B2 (en) | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
| US7615556B2 (en) | 2006-01-27 | 2009-11-10 | Bristol-Myers Squibb Company | Piperazinyl derivatives as modulators of chemokine receptor activity |
| WO2009015164A2 (en) | 2007-07-24 | 2009-01-29 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
| US8536198B2 (en) | 2007-07-24 | 2013-09-17 | Bristol-Myers Squibb Company | Piperidine derivatives as modulators of chemokine receptor activity |
| TWI433838B (zh) * | 2008-06-25 | 2014-04-11 | 必治妥美雅史谷比公司 | 作為趨化因子受體活性調節劑之六氫吡啶衍生物 |
| AR087277A1 (es) | 2011-07-21 | 2014-03-12 | Bristol Myers Squibb Co | Composiciones biodisponibles de compuestos amorfos de piperidinilo, composicion farmaceutica, metodos |
-
2009
- 2009-06-17 TW TW098120298A patent/TWI433838B/zh not_active IP Right Cessation
- 2009-06-24 US US12/490,477 patent/US8299098B2/en active Active
- 2009-06-25 CN CN2009801245643A patent/CN102076663B/zh not_active Expired - Fee Related
- 2009-06-25 PT PT97709851T patent/PT2323983E/pt unknown
- 2009-06-25 NZ NZ589909A patent/NZ589909A/en not_active IP Right Cessation
- 2009-06-25 PL PL09770985T patent/PL2323983T3/pl unknown
- 2009-06-25 DK DK09770985.1T patent/DK2323983T3/da active
- 2009-06-25 EP EP09770985.1A patent/EP2323983B1/en not_active Not-in-force
- 2009-06-25 JP JP2011516635A patent/JP5357965B2/ja not_active Expired - Fee Related
- 2009-06-25 SI SI200930827T patent/SI2323983T1/sl unknown
- 2009-06-25 MX MX2010013664A patent/MX2010013664A/es active IP Right Grant
- 2009-06-25 ES ES09770985.1T patent/ES2447740T3/es active Active
- 2009-06-25 EA EA201100088A patent/EA021224B1/ru not_active IP Right Cessation
- 2009-06-25 CA CA2729016A patent/CA2729016A1/en not_active Abandoned
- 2009-06-25 PE PE2010001176A patent/PE20110103A1/es not_active Application Discontinuation
- 2009-06-25 KR KR1020107029082A patent/KR20110023865A/ko not_active Withdrawn
- 2009-06-25 HR HRP20140071AT patent/HRP20140071T1/hr unknown
- 2009-06-25 WO PCT/US2009/048564 patent/WO2009158452A1/en not_active Ceased
- 2009-06-25 BR BRPI0914539A patent/BRPI0914539A2/pt not_active IP Right Cessation
- 2009-06-25 AU AU2009262219A patent/AU2009262219B2/en not_active Ceased
-
2010
- 2010-12-07 IL IL209832A patent/IL209832A/en not_active IP Right Cessation
- 2010-12-14 CO CO10157214A patent/CO6321247A2/es active IP Right Grant
- 2010-12-24 CL CL2010001566A patent/CL2010001566A1/es unknown
-
2012
- 2012-09-27 US US13/628,180 patent/US8633226B2/en active Active
-
2014
- 2014-03-28 CY CY20141100231T patent/CY1114994T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011526293A5 (enExample) | ||
| JP2013528656A5 (enExample) | ||
| ES2958828T3 (es) | Derivados de piridina y su uso para tratar una infección por VIH | |
| Patil et al. | Pyridine and its biological activity: a review | |
| US20170354656A1 (en) | Quinazoline Compounds | |
| JP2005194283A5 (enExample) | ||
| JP2014526503A5 (enExample) | ||
| JP2017528507A5 (enExample) | ||
| JP2010511663A5 (enExample) | ||
| EP2595620A2 (fr) | Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide | |
| JP2011528658A5 (enExample) | ||
| JP2017528503A5 (enExample) | ||
| JP2017504611A5 (enExample) | ||
| JP2017510642A5 (enExample) | ||
| JP2011068653A5 (enExample) | ||
| EP3880666B1 (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| JP2011506412A5 (enExample) | ||
| EP2043640A2 (en) | Ccr5 antagonist for enhancing immune reconstitution and treating opportunistic infection in hiv patients | |
| JP2012515788A5 (enExample) | ||
| JP2009543843A (ja) | 直接トロンビン阻害剤に関する新規適応 | |
| US10450293B2 (en) | Chemokine CXCR4 and CCR5 receptor modulators and uses related thereto | |
| US20220227707A1 (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| CN104918921A (zh) | 二唑酰胺 | |
| JP2013507377A5 (enExample) | ||
| JP2019526546A5 (enExample) |